I am a clinical scientist at University of Copenhagen and chief physician at the Department of Transplantation and Diseases of the Digestive Tract at Rigshospitalet.

If you are interested in our projects or want to collaborate, please contact me at jbseidelin@gmail.com.

My research group focus on research on inflammation in inflammatory bowel disease (IBD) and other diseases with severe intestinal inflammation in humans. The research is centred on the biology of intestinal inflammation at the mucosal level, the organ/intestinal level, and the individual level.

I have had an ongoing interest in regulation of regeneration in inflammatory bowel disease (IBD) since my PhD. It has been covering changes in apoptosis signaling as well as regeneration with focus on in vivo and in vitro experiments using patient material. I early developed a method for culture of epithelial cells from patient samples and have shown that epithelial cells in IBD generally activate cytoprotective pathways (eg. cIAPs, cFLIP and PGE2) that improve initial restitution but impair differentiation and full regeneration and block response to biological therapy. This research led to the development of the “injury model” to investigate intestinal regeneration in humans in vivo. I have in parallel had an interest in innate responses (e.g., to bacteria) in IBD. Combining these two interests, I used the “injury model” to find the early post-injury innate hyper-response in vivo in IBD as well as studying late-phase injury responses (i.e., regenerative responses) with the finding of IBD-specific lipid metabolome changes associated with delayed and dysfunctional regeneration causing intestinal damage (fibrosis) with the aim to develop therapeutic targets aimed at stopping degeneration in IBD. I have as the leading researcher in 2024 filed a patent based on these experiments.

In parallel, I have an equally strong interest in clinical research with a current focus on complicated IBD and acute severe IBD/IBD-like conditions, as these patients still suffers from high risk of treatment failure, morbidity, surgery and increased mortality with focus on advanced cross sectional imaging– as well as research in the biology (and biomarkers) of complicated disease course and intestinal damage in IBD  This includes ongoing large scale cohort studies (Prognosis; DIB; CD-FIB) and an investigator initiated RCT (VEICO). I am a member of the scientific committee of IBUS promoting use of cross sectional imaging in IBD monitoring.

The studies are performed in collaboration with researchers at UCPH (Dept of Immunology and Microbiology), U Michigan, Brigham and Women’s Hospital, University College London and other IBD centers in the Capital Region Copenhagen.

Link to UCPH profile

Link to full publication list on PubMed

Link to Google Scholar profile

Link to LinkedIn profile